Drug Development Opportunities in China: Regulation, Key Players and Initiatives for Domestic and International MarketsTuesday November 13 8:05 PMDrug Development Opportunities in China: Regulation, key players and initiatives for domestic and international markets To order that report: www.reportlinker.com/p063010/PRBW-China-Drug-Development- Market.html (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) For more information, contact Nicolas by email nbo@reportlinker.com , or by phone +33 4 37 65 17 03. Description Drug developments in the US and EU are becoming increasingly expensive and time consuming, with new products typically requiring investment of over 4 years and $1billion from concept to commercialization. As a result, China has emerged as an increasingly attractive option for companies aiming to reduce such prohibitive investments in time and finance. Human clinical studies have historically dominated outsourced R&D activities in China, with the country's relative lack of capital and expertise being insufficient to facilitate technologically intensive discovery and pre-clinical work. However, an influx of western-trained scientists and increasing access to global capital markets are rapidly extending the development opportunities available to China's expanding base of pharma and biotech companies. This report provides a comprehensive review of China's drug development industry, both in terms of expanding domestic markets and the country's role as a third-party provider of outsourced global drug developments. This report will examine the methods of expansion adopted by China's pharma companies, biotech developers and CRO's to increase the scale of their drug development operations, in addition to identifying their therapeutic interests and development lifecycle focus. It will also provide forecasts for drug development trends in China over the next five years. Identify the factors attracting global drug developers to China, assess future growth opportunities within the domestic pharma and biotech markets and deploy outsourced R&D more effectively with this new report... Table of content Executive Summary Introduction Pharmaceutical companies Biotechnology companies Contract research organizations (CROs) Future drug development in China Chapter 1 Introduction Summary The current challenges of drug development The Chinese population and economy Growth trends Culture and business environment The Chinese healthcare system The Chinese drug market Traditional Chinese medicine Western-style pharmaceuticals Patent Issues in China Drug pricing Corruption and Bribery Counterfeiting The State Food and Drug Administration Drug development in China Initiatives for the domestic market Prescription medicines Case study: AstraZeneca Over-the-counter remedies Initiatives for foreign markets Clinical trial recruiting advantages Conclusion Chapter 2 Pharmaceutical companies Summary Introduction Local players Traditional Chinese medicine Foreign players Sales and R&D activities of leading foreign pharma companies, 2007 Drivers of expansion in China Economic benefits Flexible research environment Animal Testing Stem cell research Growth constraints GMP compliance Recent developments Case study: Novo Nordisk Conclusion Chapter 3 Biotechnology companies Summary Introduction Local players Foreign players Sales and R&D activities in of leading foreign biotech companies in China, 2007 Drivers of expansion in China Increasing access to capital Public offerings Venture capital Direct investment Returning scientists Knowledge transfer from CRO work Support from Chinese-controlled drug developers abroad Government support Growth constraints Constraints on foreign biotech activity in China Constraints on domestic Chinese biotech activity Recent developments Bird flu vaccine Monoclonal antibodies Conclusion Chapter 4 Contract Research Organizations (CROs) Summary Introduction The CRO industry The role of CROs in pre-clinical trials The role of CROs in clinical trials CROs in China Local Players Case study: WuXi PharmaTech Foreign CROs Case study: Bridge Pharmaceuticals Intermediaries and agents Drivers of expansion in China Cost advantages Returning scientists Government support Networking opportunities Growth constraints Pre-clinical testing Clinical testing Conclusion Chapter 5 Future of drug development in China Summary Introduction R&D trends for the domestic market Domestic pharma R&D trends Pharma R&D expectations for 2008 and 2009 Pharma R&D expectations for 2010 to 2013 Domestic biotechnology R&D trends Domestic biotechnology R&D expectations for 2008 and 2009 Domestic biotechnology R&D expectations for 2010 to 2013 Domestic CRO R&D trends Domestic CRO R&D expectations for 2008 and 2009 Domestic CRO R&D expectations for 2010 to 2013 R&D trends for foreign markets Pharma R&D trends for foreign markets Expectations for 2008 and 2009 Expectations for 2010 to 2013 Biotechnology R&D trends for foreign markets Expectations for 2008 and 2009 Expectations for 2010 and 2013 CRO R&D trends for foreign markets Expectations for 2008 and 2009 Expectations for 2010 and 2013 Conclusion Chapter 6 Appendix Primary research methodology Index List of Figures Figure 1.1: Chinese population growth, 1950 - 2050 (est.) Figure 2.2: Growth of China's pharmaceutical drug market, 2001 - 2006 Figure 3.3: Growth of biotechnology products in China, 2001 - 2006 Figure 4.4: Timing advantages of using a CRO, 2007 Figure 4.5: Growth of CROs in China, 2001 - 2006 Figure 5.6: Pharmaceutical sales in China, 2007 - 2013 Figure 5.7: Proportion of R&D spending by type of product, 2008 and 2013 Figure 5.8: Biotech product sales in China, 2007 - 2013 Figure 5.9: CRO sales in China, 2007 - 2013 List of Tables Table 1.1: Ease of doing business in China compared with 174 other countries Table 1.2: OTC Drugs in China, 2007 Table 1.3: Advantages of working in China for pharma companies, biotech companies and CROs Table 2.4: Characteristics of China's foreign vs. domestic pharmaceutical companies, 2007 Table 3.5: Characteristics of China's foreign vs. domestic biotechnology companies, 2007 Table 3.6: Recent public offerings of Chinese biotechnology companies Table 4.7: Summary of drug testing objectives by phase Table 4.8: Leading Chinese CROs, 2007 Table 4.9: Leading foreign CROs operating in China, 2007 Table 5.10: Effect of growth drivers on drug development sectors in China, 2007 - 2013 More market research reports? Go to http://www.reportlinker.com http://market-research.typepad.com/agricultural_chemicals/ Contact: Reportlinker Nicolas Bombourg, +33 437 37 16 37 nbo@reportlinker.com |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright ©
2007
Yahoo!7 Pty Limited. All rights reserved.
Advertise with Us -
Privacy Policy - Terms of Service.